Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BMS-820132 · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| Arm 1 BMS-820132 or placebo | ACTIVE_COMPARATOR | - |
| Arm 2 BMS-820132 or placebo | ACTIVE_COMPARATOR | - |
| Arm 3 BMS-820132 or placebo | ACTIVE_COMPARATOR | - |
| Arm 4 BMS-820132 or placebo | ACTIVE_COMPARATOR | - |
| Arm 5 BMS-820132 or placebo | ACTIVE_COMPARATOR | - |
| Arm 6 BMS-820132 or placebo | ACTIVE_COMPARATOR | - |
| Arm 7 BMS-820132 or placebo | ACTIVE_COMPARATOR | - |
| Arm 8 BMS-820132 or placebo | ACTIVE_COMPARATOR | - |
| Arm 9 BMS-820132 or placebo | ACTIVE_COMPARATOR | - |
| BMS-820132 (0.3 mg) or Placebo | ACTIVE_COMPARATOR | - |
| BMS-820132 (1.0 mg) or Placebo | ACTIVE_COMPARATOR | - |
| BMS-820132 (3 mg) or Placebo | ACTIVE_COMPARATOR | - |
| BMS-820132 (10 mg) or Placebo | ACTIVE_COMPARATOR | - |
| BMS-820132 (30 mg) or Placebo | ACTIVE_COMPARATOR | - |
| BMS-820132 (75 mg) or Placebo | ACTIVE_COMPARATOR | - |
| BMS-820132 (150 mg) or Placebo | ACTIVE_COMPARATOR | - |
| BMS-820132 (300 mg) or Placebo | ACTIVE_COMPARATOR | - |
| BMS-820132 (TBD) or Placebo | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | capsule, Oral, 0.0mg, twice daily, 14 day |
| BMS-820132 | DRUG | Capsule, Oral, 15mg, twice daily, 14 day |
Inclusion Criteria: * Males and females of childbearing potential (willing to use an acceptable method of contraception), or females of non-childbearing potential (i.e., post-menopausal or surgically sterile). * Diagnosis of type 2 diabetes treated with metformin monotherapy (at least 1500 mg/day f...
BMS-820132 is an investigational small molecule being developed for the treatment of Type 2 Diabetes Mellitus, also referred to as Non-Insulin-Dependent Diabetes Mellitus. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
BMS-820132 is being developed by Bristol-Myers Squibb Company, which trades on the New York Stock Exchange under the ticker symbol BMY. The company is conducting clinical trials of this investigational drug in patients with Type 2 Diabetes.
BMS-820132 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved for commercial use. Two Phase 1 studies have been completed, and the drug remains under evaluation for safety and tolerability in patients with Type 2 Diabetes.
BMS-820132 has been studied in two completed Phase 1 clinical trials. NCT01105429 was a single ascending dose study in 56 patients with Type 2 Diabetes, and NCT01290575 was a multiple ascending dose study in 67 patients with Type 2 Diabetes. Both trials were conducted in the United States.
No alternative names for BMS-820132 have been disclosed. The drug is identified solely by its compound code BMS-820132 in clinical trial registrations and development records.